Relationship between the Mutation of IRS-1 Gene and β_3-adrenergic Receptor Gene

Ｏｂｅｓｉｔｙｉｓａｓｓｏｃｉａｔｅｄｗｉｔｈｉｎｓｕｌｉｎｒｅｓｉｓ ｔａｎｃｅ (ＩＲ) ,ｗｈｉｃｈｐｌａｙｓａｃｒｉｔｉｃａｌｒｏｌｅｉｎｔｈｅｄｅｖｅｌｏｐｍｅｎｔｏｆｔｙｐｅ 2ｄｉａｂｅｔｅｓｍｅｌｌｉｔｕｓ.ＴｈｅｍｅｃｈａｎｉｓｍｏｆＩＲｉｓｒｅｌａｔｅｄｔｏｔｈｅａｂｎｏｒｍａｌｉｔｉｅｓｏｆｉｎｓｕｌｉｎｒｅｃｅｐｔｏｒ,ｐｒｅ ｒｅｃｅｐｔｏｒ,ｐｏｓｔ ｒｅｃｅｐ ｔｏｒ ,ｒｅｓｕｌｔｉｎｇｉｎｄｅｆｅｃｔｉｖｅｍｅｔａｂｏｌｉｃｐａｔｈｗａｙｏｆｇｌｕｃｏｓｅ,ｌｉｐｉｄａｎｄ ｐｒ…     

竹黄通痹胶囊治疗痛风43例

目的：为寻求一种对治疗痛风病更为有效而且服用方便的方药。方法：门诊收治的43例患,根据临床表现,化验室检查和X线摄片而确诊。每日口服“竹黄通痹胶囊”连续服用3个月。结果：43例患临床痊愈30例,有效11例,无效2例,总有效率为95．4％。结论：竹黄通痹胶囊具有清热利湿,活血通络,消肿止痛等作用,且无不良反应。     

体外观察维甲酸对NIH/3T3细胞的抑制作用

目的评价维甲酸(RA)对NIH/3T     

银杏黄酮甙和甲基B_(12)联合治疗糖尿病周围神经病变的疗效观察

目的　探讨银杏黄酮甙和甲基B12 对糖尿病周围病变的治疗效果。方法　将 14 9例糖尿病周围神经病变患者随机分为 4组 ,分别为常规治疗组 (对照组 )、银杏黄酮甙组 (第 1组 )、甲基B12 组 (第 2组 )、银杏黄酮甙与甲基B12 联合组(第 3组 )。疗程为 8周。观察治疗前后自觉症状、腱反射和神经传导速度。结果　第 3组总有效率为 95 % ,显著高于对照组 (17% ) (P <0 .0 0 5 )。第 1组和第 2组 ,总有效率分别为 6 9%和 72 % ,与对照组比较均有显著差异 (P <0 .0 1)。第 3组神经传导速度治疗后较冶疗前显著改善 (P <0 .0 1) ,而且显著优于对照组 (P <0 .0 1)、第 1组 (P <0 .0 5 )和第 2组 (P <0 .0 5 )。结论　银杏黄酮甙和甲基B12 联合治疗糖尿病周围神经病变较单独应用更为有效。     

Intradialytic systolic blood pressure variation can predict long-term mortality in patients on maintenance hemodialysis

International Urology and Nephrology - It is unclear which time-points of intradialytic blood pressure (BP) best predict prognosis. Thus, it is important to assess the association between different...     

Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocol

International Urology and Nephrology - The aim of this study is to evaluate the intra/perioperative fluid management and early postoperative outcomes of patients who underwent radical cystectomy...     

Clinicopathological characteristics,prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma

PurposeTo investigate the clinical characteristics, chemosensitivity, and outcome of metastatic upper tract urothelial carcinoma (UTUC).Patients and MethodsRecords of patients with metastatic UTUC since January 2005 were retrieved from a database that included clinical and survival data. Statistical analyses including survival and multivariate analyses of factors were respectively performed by the Kaplan-Meier method and Cox proportional hazard model.ResultsA total of 250 consecutive UTUC cases were evaluated. There were 56 patients (22.4%) with initially diagnosed stage IV disease. The most common metastatic sites were lung (39.6%), distant lymph nodes (39.2%), bone (19.6%), liver (18.0%), and adrenal gland (7.2%), respectively, and the local recurrence rate was 10.4%. Two hundred thirteen patients received first-line chemotherapy. The overall response rate was only 28.7% and the median progression-free survival time was only 5.0 months. The overall survival time of the cohort was 18.0 months. Multivariate analyses showed that initially diagnosed stage IV disease, number of metastatic organs ≥3, no response to chemotherapy and cycles of chemotherapy ≤2 were adverse prognosticators for overall survival.ConclusionUTUC presented to be more prone to metastasize than locally recur and thought to have low chemosensitivity. Stage IV disease at initial diagnosis, number of metastatic organs, response and cycles of chemotherapy were independent prognosticators for metastatic UTUC.     

Adverse events involving hallux metatarsophalangeal joint implants: Analysis of the United States Food and Drug Administration data from 2010 to 2018

BackgroundThe prevalence of osteoarthritis of the hallux metatarsophalangeal joint (MTPJ) is 1 in 40 people over the age of 50. Surgical treatment options for MTPJ arthritis include joint preservation, joint resurfacing, and arthrodesis. Hallux MTPJ implants have evolved over the past several decades, but are associated with various complications. The aim of this study was to examine the MAUDE database to determine reported adverse events for hallux MTPJ implants.Materials and methodsThe US Food and Drug Administration’s (FDA) Manufacturer and User Facility Device Experience (MAUDE) database was reviewed from 2010 to 2018 to review voluntary reported adverse event reports for approved implants within the United States. We recorded the type of adverse event and excluded duplicate reports and those extracted from already published literature.ResultsAmong 64 reported hallux MTPJ implant adverse events, the most common modes of adverse events were component loosening (34%), infection (14.1%), component fracture (9.4%), inflammation (9.4%), and allergic reaction (7.8%). Regarding implant type, Cartiva SCI had the highest percentage of adverse events (23.4%), followed by Arthrosurface ToeMotion (20.3%), Ascension MGT (12.5%), Arthrosurface HemiCAP® (10.9%), Futura primus (9.4%), and Osteomed Reflexion (6.3%). There was an increase in reported adverse events after 2016. The MAUDE database does not report the total incidence of implant insertion.ConclusionOur study of the MAUDE database demonstrated that component loosening and infection are the most common modes of adverse events for hallux MTPJ implants. Cartiva accounted for one-fourth of the implant-related adverse events during our study period, followed by ToeMotion, and Ascension MGT implants. Continued reporting of adverse events will improve our understanding on short and long-term complications of various hallux MTPJ implants.Level of evidenceLevel IV; Case Series from Large Database Analysis; Treatment Study.     

Comparison of the anxiety,depression and their relationship to quality of life among adult acute leukemia patients and their family caregivers: a cross-sectional study in China

Quality of Life Research - To compare the anxiety, depression and explore their relationship to quality of life (QoL) among adult acute leukemia (AL) patients and family caregivers (FCs) in China....